Dawn Bio is a drug discovery platform utilizing human embryo models to advance research in women's reproductive health. The platform addresses the lack of effective treatments and therapies specifically tailored for women's reproductive conditions.
Funding
$580K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
In vitro fertilization (IVF) faces challenges with low success rates, as more than two out of three embryo transfers fail, resulting in many patients having only one or two good-quality blastocysts available. Current IVF practices primarily focus on selecting the "best" embryo from a limited pool, rather than improving the overall quality and quantity of viable embryos. This limitation hinders the ability to effectively address infertility and improve outcomes for patients undergoing IVF.
Solution
Dawn Bio is developing a stem-cell based platform technology focused on decoding biological signals that embryos need to thrive. By combining stem-cell based embryo and implantation models with deep tech insights, Dawn Bio aims to enable IVF clinics to create more and healthier embryos. This approach shifts the focus from selecting the best embryo to fundamentally improving the conditions for early embryo development and implantation, ultimately increasing the chances of successful IVF outcomes for patients.
Target Audience
The primary target audience includes IVF clinics and reproductive medicine centers seeking to improve their success rates and offer more effective treatments to patients struggling with infertility.
Features
- Human stem-cell based embryo and implantation model for research and product development.
- Technology to decode biological signals crucial for early human embryo development.
- Tools for improving the quantity and quality of embryos in IVF settings.